Clinical Research Directory
Browse clinical research sites, groups, and studies.
Evaluation of Effectiveness and Safety of LC16m8 Mpox Vaccine in the Democratic Republic of Congo (DRC)
Sponsor: International Vaccine Institute
Summary
This is a health facility-based prospective test-negative (TND) case-control study to evaluate vaccine effectiveness and active safety monitoring (cohort event monitoring), and passive surveillance for evaluation of the safety of the LC16m8 mpox vaccine in individuals aged one year and older in the DRC. This study aims to assess the LC16m8 vaccine effectiveness and safety. The following activities will be carried out: * Community engagement * Enhanced health facility-based mpox disease surveillance * Vaccination using the LC16m8 vaccine * Safety monitoring following immunization * LC16m8 Vaccine effectiveness evaluation using a TND Study Hypothesis: The LC16m8 vaccine, administered as pre-exposure prophylaxis, confers greater than 70% protection against symptomatic mpox disease among adults and children in the DRC.
Official title: Evaluation of the Effectiveness and Safety of the LC16m8 Mpox Vaccine in Individuals Aged One Year and Older in the Democratic Republic of Congo (DRC)
Key Details
Gender
All
Age Range
1 Year - Any
Study Type
OBSERVATIONAL
Enrollment
11990
Start Date
2025-09-30
Completion Date
2027-12-31
Last Updated
2025-09-15
Healthy Volunteers
Yes
Conditions
Interventions
LC16m8
LC16m8 vaccine will be offered to all individuals aged \>1 year and meet the inclusion criteria within the catchment population. This will be done in line with the DRC government's LC16m8 vaccine roll out plan.
Locations (1)
The Institut National de la Recherche Biomédicale (INRB)
Kinshasa, Democratic Republic of the Congo